Skip to main content

International Psoriasis Council

International Psoriasis Council
subscribe
6   What's New
Search
subscribe
Search

Advancing Knowledge. Improving Care.

Fernando Valenzuela Headshot

Fernando

Valenzuela

,

MD

Full-time Professor of Dermatology
University of Chile, University of the Andes
Santiago
,
Chile
Councilor Since: March 1, 2015
IPC Councilor
Request an Update
Dr. Fernando Valenzuela is currently a Full-time Professor of Dermatology at the University of Chile and the University of the Andes in Santiago, Chile. He has received multiple awards from his medical school days and works closely with Dr. Kim Papp in Probity Medical Research doing clinical trials. He is highly regarded by his colleagues in Latin America and attends all SOLAPSO and RADLA meetings, where he is frequently featured as a main speaker. He has been working and publishing about new agents in psoriasis, quality of life, and comorbidities. He is the Chilean Coordinator of Global Psoriasis Atlas, the President of 2022 RADLA, and the Head of the Department of Dermatology at the University of Chile. He is active in the IPC Latin America working group and has been an IPC Councilor since 2015.
Last Updated:
11/22/2024

Areas of Interest

Psoriasis and quality of life, periodontal health in psoriasis and new treatments.

IPC Committees / Groups

Fellowship Program Advisory Committee, Latin America Working Group

Languages Spoken

English, Spanish
Recent publications

Featured

Video

Complementary Strategies in Psoriasis.

IPC Councilor Dr. Fernando Valenzuela reviews non-pharmacological strategies for managing psoriasis, covering diet,…

Watch Video

Video

Estrategias Complementarias en Psoriasis.

El Dr. Fernando Valenzuela, Consejero de IPC, repasa las estrategias no farmacológicas para el manejo de la psoriasis,…

Watch Video

PDF

A Report from the 34th Annual European Academy of Dermatology and Venereology (EADV) Congress.

Key takeaways from the 2025 EADV Congress in Paris, including the IPC Symposium on psoriasis, Free Communication…

View Report

Video

Phototherapy in Pediatric Psoriasis.

IPC Councilor Dr. Fernando Valenzuela explains how phototherapy can be effectively used to treat psoriasis in pediatric…

Watch Video

Video

Relación Entre la Salud Oral y la Psoriasis.

En este video de Take Ten con IPC, el Dr. Fernando Valenzuela analiza la conexión entre la salud oral y la psoriasis,…

Watch Video

Video

Relationship Between Oral Health and Psoriasis.

In this Take Ten with IPC video, Dr. Fernando Valenzuela explores the connection between oral health and psoriasis,…

Watch Video

Video

Fototerapia (español).

El Dr. Fernando Valenzuela analiza las ventajas y desventajas de la fototerapia como opción de tratamiento para…

Watch Video

Event

IPC & SOLAPSO Symposium: Psoriasis and Infections: A Latin American Prospective.

REUNIÓN ANUAL DE DERMATÓLOGOS LATINOAMERICANOS (RADLA) | LIMA, PERÚ Tuesday, May 7 09:00– 12:00 PET Program…

May 7, 2024
Learn More or Register

Blog

World Psoriasis Day 2023: Empowering Access to Timely Treatment and Universal Healthcare from Psoriasis Advocates…

IPC stands for accessible treatment and universal healthcare on World Psoriasis Day and beyond. Gain insights from…

Read More

Video

Cómo Trato las Uñas.

Dr. Fernando Valenzuela discusses how he treats nail psoriasis in his daily practice. El Dr. Fernando Valenzuela…

Watch Video

Blog

Meet Our 2022 Volunteers of the Year.

The IPC’s global network of experts generously volunteers their time every year to educate and train other physicians…

Read More

Event

IPC & SOLAPSO Symposium: Advances in the Management of Psoriasis.

REUNIÓN ANUAL DE DERMATÓLOGOS LATINOAMERICANOS (RADLA) | CURITIBA, BRAZIL Friday, May 26 14:00 – 17:00 BRT 13:00…

May 26, 2023
Learn More or Register

Blog

Un Enfoque en Psoriasis: Un Reporte de el Congreso RADLA 2022.

La XXXIX Reunión Anual de Dermatólogos Latinoamericanos (RADLA) se realizó de manera virtual del 2 al 5 de mayo,…

Read More

Blog

Latin American Case Series.

It is not fully understood the impact that COVID-19 has on psoriasis patients. .

Read More

Blog

World Psoriasis Day.

Biologics and biosimilars have created many new options in psoriasis treatment for patients worldwide, but patients…

Read More

PDF

Psoriasis and Mental Health Workshop Report: Exploring the Links between Psychosocial Factors, Psoriasis,…

View Report

PDF

Clinical Goals and Barriers to Effective Psoriasis Care.

View Report

Page

Biosimilars in Psoriasis: Clinical Practice and Regulatory Perspectives in Latin America.

Latin American countries view biosimilar agents as an effective approach to curtail health-care expenditures while…

View Report

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026